BI Asset Management Fondsmaeglerselskab A S Sells 919 Shares of Hologic, Inc. (NASDAQ:HOLX)

BI Asset Management Fondsmaeglerselskab A S lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 6.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,821 shares of the medical equipment provider’s stock after selling 919 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Hologic were worth $1,000,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in Hologic in the fourth quarter valued at approximately $217,529,000. The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 117.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after purchasing an additional 1,168,564 shares during the period. Jennison Associates LLC bought a new stake in Hologic in the fourth quarter valued at about $30,079,000. Cubist Systematic Strategies LLC lifted its stake in Hologic by 207.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 538,814 shares of the medical equipment provider’s stock valued at $38,498,000 after buying an additional 363,796 shares during the period. Finally, Nuance Investments LLC bought a new position in Hologic during the fourth quarter worth about $24,431,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Up 0.1 %

NASDAQ HOLX traded up $0.08 during trading on Wednesday, hitting $74.83. The stock had a trading volume of 206,443 shares, compared to its average volume of 1,612,429. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $82.45. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The company’s 50-day moving average price is $74.00 and its two-hundred day moving average price is $74.47. The company has a market capitalization of $17.46 billion, a PE ratio of 38.12, a P/E/G ratio of 2.48 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm posted $1.06 earnings per share. The firm’s revenue for the quarter was down .8% on a year-over-year basis. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Argus upped their price target on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Evercore ISI reduced their price target on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 2nd. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.